145 related articles for article (PubMed ID: 29620216)
1. Doxycycline targets aldehyde dehydrogenase‑positive breast cancer stem cells.
Lin CC; Lo MC; Moody RR; Stevers NO; Tinsley SL; Sun D
Oncol Rep; 2018 Jun; 39(6):3041-3047. PubMed ID: 29620216
[TBL] [Abstract][Full Text] [Related]
2. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells.
Lee CH; Hong HM; Chang YY; Chang WW
Biochimie; 2012 Jun; 94(6):1382-9. PubMed ID: 22445681
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells.
De Luca A; Fiorillo M; Peiris-Pagès M; Ozsvari B; Smith DL; Sanchez-Alvarez R; Martinez-Outschoorn UE; Cappello AR; Pezzi V; Lisanti MP; Sotgia F
Oncotarget; 2015 Jun; 6(17):14777-95. PubMed ID: 26087310
[TBL] [Abstract][Full Text] [Related]
5. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer.
Zhang L; Xu L; Zhang F; Vlashi E
Cell Cycle; 2017 Apr; 16(8):737-745. PubMed ID: 27753527
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the Therapeutic Potential of Antibiotics in Hypoxia in a Breast Cancer MCF-7 Cell Line Model.
Akhunzianov AA; Nesterova AI; Wanrooij S; Filina YV; Rizvanov AA; Miftakhova RR
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511298
[TBL] [Abstract][Full Text] [Related]
8. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
9. Effects of ellipticine on ALDH1A1-expressing breast cancer stem cells--an in vitro and in silico study.
Pandrangi SL; Chikati R; Chauhan PS; Kumar CS; Banarji A; Saxena S
Tumour Biol; 2014 Jan; 35(1):723-37. PubMed ID: 23982874
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress induces senescence in breast cancer stem cells.
Zhong G; Qin S; Townsend D; Schulte BA; Tew KD; Wang GY
Biochem Biophys Res Commun; 2019 Jul; 514(4):1204-1209. PubMed ID: 31109646
[TBL] [Abstract][Full Text] [Related]
11. Targeting aberrant expression of Notch-1 in ALDH
Pal D; Kolluru V; Chandrasekaran B; Baby BV; Aman M; Suman S; Sirimulla S; Sanders MA; Alatassi H; Ankem MK; Damodaran C
Mol Carcinog; 2017 Mar; 56(3):1127-1136. PubMed ID: 27753148
[TBL] [Abstract][Full Text] [Related]
12. Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy.
Lamb R; Fiorillo M; Chadwick A; Ozsvari B; Reeves KJ; Smith DL; Clarke RB; Howell SJ; Cappello AR; Martinez-Outschoorn UE; Peiris-Pagès M; Sotgia F; Lisanti MP
Oncotarget; 2015 Jun; 6(16):14005-25. PubMed ID: 26087309
[TBL] [Abstract][Full Text] [Related]
13. Targeting human brain cancer stem cells by curcumin-loaded nanoparticles grafted with anti-aldehyde dehydrogenase and sialic acid: Colocalization of ALDH and CD44.
Kuo YC; Wang LJ; Rajesh R
Mater Sci Eng C Mater Biol Appl; 2019 Sep; 102():362-372. PubMed ID: 31147008
[TBL] [Abstract][Full Text] [Related]
14. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
15. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
16. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaΒ-inducing kinase regulates stem cell phenotype in breast cancer.
Vazquez-Santillan K; Melendez-Zajgla J; Jimenez-Hernandez LE; Gaytan-Cervantes J; Muñoz-Galindo L; Piña-Sanchez P; Martinez-Ruiz G; Torres J; Garcia-Lopez P; Gonzalez-Torres C; Ruiz V; Avila-Moreno F; Velasco-Velazquez M; Perez-Tapia M; Maldonado V
Sci Rep; 2016 Nov; 6():37340. PubMed ID: 27876836
[TBL] [Abstract][Full Text] [Related]
18. Ursolic acid inhibits the proliferation of triple‑negative breast cancer stem‑like cells through NRF2‑mediated ferroptosis.
Yang X; Liang B; Zhang L; Zhang M; Ma M; Qing L; Yang H; Huang G; Zhao J
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38847277
[TBL] [Abstract][Full Text] [Related]
19. Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs).
Fiorillo M; Tóth F; Sotgia F; Lisanti MP
Aging (Albany NY); 2019 Apr; 11(8):2202-2216. PubMed ID: 31002656
[TBL] [Abstract][Full Text] [Related]
20. Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity.
Giordano C; Chemi F; Panza S; Barone I; Bonofiglio D; Lanzino M; Cordella A; Campana A; Hashim A; Rizza P; Leggio A; Győrffy B; Simões BM; Clarke RB; Weisz A; Catalano S; Andò S
Oncotarget; 2016 Jan; 7(2):1262-75. PubMed ID: 26556856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
